At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 339 enrolled
Drug / intervention
Insulin Lispro Protamine Suspension +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Trial Comparing Insulin Lispro Protamine Suspension With Insulin Glargine in Subjects With Type 2 Diabetes on Oral Antihyperglycemic Medications and Exenatide
In Brief
A Phase 3 clinical trial evaluating Insulin Lispro Protamine Suspension and Insulin Glargine for Diabetes Mellitus, Type 2. Completed, enrolled 339 participants across 52 sites in 2 countries.
Detailed Summary
This study will compare insulin lispro protamine suspension (ILPS) and insulin glargine in combination with the patient's oral diabetes medications and exenatide, for their ability to control blood sugar in patients with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
First PostedNov 2007
Primary CompletionDec 2009
TodayJul 2026
First PostedNov 19, 2007
Enrollment StartNov 1, 2007
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 18.6 years ago
Interventions
Insulin Lispro Protamine Suspensiondrug
Administered subcutaneously once a day at bedtime
Insulin Glarginedrug
Administered subcutaneously once a day at bedtime